Adjuvant radiotherapy for uterine carcinosarcoma: A retrospective assessment of treatment outcomes

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Ugur
dc.contributor.authorAlanyali, Senem
dc.contributor.authorAras, Arif Bulent
dc.contributor.authorOzsaran, Zeynep
dc.date.accessioned2024-04-24T17:24:15Z
dc.date.available2024-04-24T17:24:15Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: The objective of the study is to understand the impact of adjuvant radiotherapy (RT) and prognostic factors for patients diagnosed with uterine carcinosarcoma.Materials and Methods: The records of 31 patients receiving adjuvant RT between the dates of September 2003-January 2013 in our clinic were evaluated retrospectively. Surgery was performed in 27 (87%) patients as staging laparotomy, for 4 patients as total abdominal hysterectomy and bilateral salpingo-oophorectomy. Pelvic external beam radiotherapy (EBRT) was 4500-5040 cGy in 25-28 fractions. In addition, 23 patients received brachytherapy following EBRT, 12 patients received adjuvant, and 1 patient received neoadjuvant chemotherapy (CT).Results: The median age was 63 (between 30 and 78). The stage distribution of the patients was as follows: Stage I, 20 (64%); Stage II, 7 (23%), and Stage III, 4 (13%) patients. Five-year locoregional control (LRC) rate was 100%, disease-free survival (DFS) and overall survival (OS) rates were 65.5% and 66.2%, respectively. Stage I or II patients have a tendency for better 5-year OS and DFS rates than Stage III patients (73.1% vs. 42.9% and 72.7% vs. 42.9%; P = 0.065 and 0.051). Regarding lymph node dissection was performed or not, 5-year OS (64.7% vs. 75.0%) was not statistically different between groups (P = 0.77). Five-year OS and DFS rates were 69.2% and 61.5% for patients receiving CT (adjuvant or neoadjuvant) versus 63.7% and 68.8% for patients not receiving CT; P = 0.63 and P = 0.89, respectively. Based on the analysis of peritoneal washings, 5-year OS was 0% for patients with malignant or suspicious cytology whereas 89% for patients with benign cytology (P = 0.000). A negative correlation was observed between mitotic count of sarcomatous component and DFS time (rs = -0.812 and P = 0.05).Conclusions: Surgery and adjuvant RT seem beneficial for excellent LRC rate. However, survival rates are low due to distant metastases. Thus, there is a great need for better systemic therapies.en_US
dc.identifier.doi10.4103/jcrt.JCRT_531_18
dc.identifier.endpage1382en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue6en_US
dc.identifier.pmid31898676
dc.identifier.startpage1377en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_531_18
dc.identifier.urihttps://hdl.handle.net/11468/19562
dc.identifier.volume15en_US
dc.identifier.wosWOS:000506393900030
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal of Cancer Research and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRadiotherapyen_US
dc.subjectSurvivalen_US
dc.subjectUterine Carcinosarcomaen_US
dc.titleAdjuvant radiotherapy for uterine carcinosarcoma: A retrospective assessment of treatment outcomesen_US
dc.titleAdjuvant radiotherapy for uterine carcinosarcoma: A retrospective assessment of treatment outcomes
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu